Immunotherapeutics in Development for Prostate Cancer-Reference-Cited by-同舟云学术

Immunotherapeutics in Development for Prostate Cancer

Published:2009-04-01 Issue:4 Volume:14 Page:391-398
ISSN:1083-7159
Container-title:The Oncologist
language:en
Short-container-title:

Author:

Harzstark Andrea L.¹,Small Eric J.¹

Affiliation:

1. a Department of Medicine, University of California – San Francisco, San Francisco, California, USA

Abstract

Abstract Whereas chemotherapy is the standard of care for metastatic castration-resistant prostate cancer and is associated with a survival benefit, there remains a need for alternative approaches. Extensive work has been done evaluating multiple immunotherapies for the treatment of prostate cancer. This review discusses clinical results for the most promising developments. These include cytokine-based therapy with GM-CSF; vaccines; antibody-based immunotherapies, including anti–cytotoxic T lymphocyte associated antigen 4 therapy and antibodies against additional targets; and dendritic cell-based immunotherapy.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.2008-0240

Reference50 articles.

1. Demonstration of a rational strategy for human prostate cancer gene therapy;Sanda;J Urol,1994

2. Autoantibody signatures in prostate cancer;Wang;N Engl J Med,2005

3. Granulocyte-macrophage colony-stimulating factor as an adjuvant in tumor immunotherapy;Fagerberg;Med Oncol,1996

4. New therapeutic modalities for the clinical use of rhGM-CSF in patients with malignancies;Schulz;Am J Clin Oncol,1991

5. Potential clinical applications of rhGM-CSF in acute myeloid leukemia based on its biologic activity and receptor interaction;Lanza;Haematologica,1997

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Intravesical immunotherapy with a GM-CSF armed oncolytic vesicular stomatitis virus improves outcome in bladder cancer;Molecular Therapy - Oncolytics;2022-03

2. Combination immunotherapy induces distinct T-cell repertoire responses when administered to patients with different malignancies;Journal for ImmunoTherapy of Cancer;2020-05

3. NK-Cell Recruitment Is Necessary for Eradication of Peritoneal Carcinomatosis with an IL12-Expressing Maraba Virus Cellular Vaccine;Cancer Immunology Research;2017-02-03

4. Interleukin-7;Cancer Therapeutic Targets;2017

5. Immunothérapie dans les cancers de la prostate;Bulletin du Cancer;2016-11